Cargando…
COVID-19 vaccine prioritisation for type 1 and type 2 diabetes
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831734/ https://www.ncbi.nlm.nih.gov/pubmed/33476583 http://dx.doi.org/10.1016/S2213-8587(21)00017-6 |
| _version_ | 1783641680485810176 |
|---|---|
| author | Powers, Alvin C Aronoff, David M Eckel, Robert H |
| author_facet | Powers, Alvin C Aronoff, David M Eckel, Robert H |
| author_sort | Powers, Alvin C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7831734 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78317342021-01-26 COVID-19 vaccine prioritisation for type 1 and type 2 diabetes Powers, Alvin C Aronoff, David M Eckel, Robert H Lancet Diabetes Endocrinol Correspondence Elsevier Ltd. 2021-03 2021-01-18 /pmc/articles/PMC7831734/ /pubmed/33476583 http://dx.doi.org/10.1016/S2213-8587(21)00017-6 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Powers, Alvin C Aronoff, David M Eckel, Robert H COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title | COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title_full | COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title_fullStr | COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title_full_unstemmed | COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title_short | COVID-19 vaccine prioritisation for type 1 and type 2 diabetes |
| title_sort | covid-19 vaccine prioritisation for type 1 and type 2 diabetes |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831734/ https://www.ncbi.nlm.nih.gov/pubmed/33476583 http://dx.doi.org/10.1016/S2213-8587(21)00017-6 |
| work_keys_str_mv | AT powersalvinc covid19vaccineprioritisationfortype1andtype2diabetes AT aronoffdavidm covid19vaccineprioritisationfortype1andtype2diabetes AT eckelroberth covid19vaccineprioritisationfortype1andtype2diabetes |